These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18615711)

  • 1. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
    Mace AT; Ganly I; Soutar DS; Brown SM
    Head Neck; 2008 Aug; 30(8):1045-51. PubMed ID: 18615711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
    Fujimoto Y; Mizuno T; Sugiura S; Goshima F; Kohno S; Nakashima T; Nishiyama Y
    Acta Otolaryngol; 2006 Oct; 126(10):1115-7. PubMed ID: 16923721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
    Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
    Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.
    Ogawa F; Takaoka H; Iwai S; Aota K; Yura Y
    Anticancer Res; 2008; 28(6A):3637-45. PubMed ID: 19189645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
    Mace AT; Harrow SJ; Ganly I; Brown SM
    Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
    Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
    Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
    Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
    Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.
    Papanastassiou V; Rampling R; Fraser M; Petty R; Hadley D; Nicoll J; Harland J; Mabbs R; Brown M
    Gene Ther; 2002 Mar; 9(6):398-406. PubMed ID: 11960316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma.
    Yu Z; Li S; Huang YY; Fong Y; Wong RJ
    Cancer Gene Ther; 2007 Aug; 14(8):738-47. PubMed ID: 17525764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.
    Conner J; Braidwood L
    Cancer Gene Ther; 2012 Jul; 19(7):499-507. PubMed ID: 22595793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
    Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
    Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients.
    Streby KA; Geller JI; Currier MA; Warren PS; Racadio JM; Towbin AJ; Vaughan MR; Triplet M; Ott-Napier K; Dishman DJ; Backus LR; Stockman B; Brunner M; Simpson K; Spavin R; Conner J; Cripe TP
    Clin Cancer Res; 2017 Jul; 23(14):3566-3574. PubMed ID: 28495911
    [No Abstract]   [Full Text] [Related]  

  • 14. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
    Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B; Reid T; Kaye S; Kirn D
    Cancer Res; 2000 Nov; 60(22):6359-66. PubMed ID: 11103798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
    Griffith C; Noonan S; Lou E; Shillitoe EJ
    Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.
    Detta A; Harland J; Hanif I; Brown SM; Cruickshank G
    J Gene Med; 2003 Aug; 5(8):681-9. PubMed ID: 12898637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
    Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
    Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.